Kolexia
D'Aveni-Piney Maud Hématologie
D'Aveni-Piney Maud
Hématologie
Hôpital Brabois
Vandoeuvre-lès-Nancy, France
119 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie du greffon contre l'hôte Syndromes myélodysplasiques Leucémies Anémie COVID-19 Leucémie aigüe myéloïde Maladie aigüe Infections à Adenoviridae Maladies virales

Collaborateurs

Voir plus
Rubio Marie-Therese
Rubio Marie-Therese
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Nguyen-Quoc Stephanie
Nguyen-Quoc Stephanie
Hôpital Pitie Salpetriere, Paris, France
Campidelli Arnaud
Campidelli Arnaud
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Notarantonio Anne-Béatrice
Notarantonio Anne-Béatrice
Hôpital Brabois, Vandoeuvre-lès-Nancy, France

Industries

Voir plus
Novartis
10 collaboration(s)
Dernière en 2023
BMS
9 collaboration(s)
Dernière en 2023
Janssen
8 collaboration(s)
Dernière en 2023
Celgene
6 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
ELEMENT-MDS: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-Naive Participants Who Are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial
Essai Clinique (BMS)   11 mars 2024
On behalf of the SFGM-TC: Real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients.
HemaSphere   27 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
Thrombopénie immunologique après allogreffe de cellules souches hématopoïétiques : résultats d’une étude rétrospective observationnelle multicentrique portant sur 35 patients
87e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE   01 décembre 2023
Comparison of two reduced intensity conditioning regimens: Flu-Bu2 versus RIC-TBF in allogeneic hematopoietic stem cell transplantation.
Leukemia & lymphoma   21 novembre 2023
HAPLO-EMPTY: Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression: a Nationwide Phase II Study
Essai Clinique (Assistance publique – Hôpitaux de Paris)   21 novembre 2023
Efficacy and Safety of Luspatercept +/- Erythropoiesis-Stimulating Agent (ESA) in Patients with Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS): A French Multicenter Prospective Real-Life Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes
65th ASH Annual Meeting Abstracts   02 novembre 2023
IDUNN: A Randomised, Open-label, Multicentre, Phase 3 Trial of First-line Treatment With Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects With Steroid-refractory Acute Graft-versus-host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)
Essai Clinique (medac GmbH)   02 novembre 2023
Senescence and Mitochondrial Transfer Ability of Bone Marrow Mesenchymal Stromal Cells Influence Patterns of Alloreactivity after Allogeneic Hematopoietic Stem Cell Transplantation
65th ASH Annual Meeting Abstracts   02 novembre 2023